Genentech in-licenses prostate cancer program

Genentech has agreed to license an experimental therapy for prostate cancer from Protein Design Labs. No details were released, but Protein Design will receive an upfront fee and milestones for the successful development of a therapy. Protein Design had originally in-licensed the program from Seattle Genetics.

- read this story from the AP for more

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.